Enzastaurin
From Infogalactic: the planetary knowledge core
180px | |
Names | |
---|---|
IUPAC name
3-(1-Methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
|
|
Other names
LY-317615
|
|
Identifiers | |
170364-57-5 ![]() |
|
ChEMBL | ChEMBL300138 ![]() |
ChemSpider | 153463 ![]() |
5693 | |
Jmol 3D model | Interactive image |
PubChem | 176167 |
UNII | UC96G28EQF ![]() |
|
|
|
|
Properties | |
C32H29N5O2 | |
Molar mass | 515.62 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply, preventing growth.
In 2013 it failed a phase III clinical trial for lymphoma.[1]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Enzastaurin hydrochloride, National Institutes of Health